PCM
FLNA

Prelude Capital Management’s Filana Therapeutics FLNA Stock Holding History

Prelude Capital Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,900
Closed -$214K – 2168
2021
Q4 		$214K Buy
+4,900
New +$257K 0.01% 1529
2020
Q3 		– Sell
-1,800
Closed -$6K – 2274
2020
Q2 		$6K Buy
+1,800
New +$8.16K ﹤0.01% 1689
2014
Q2 		– Sell
-286
Closed -$11K – 2134
2014
Q1 		$11K Buy
+286
New +$10.1K ﹤0.01% 1757

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Prelude Capital Management's FLNA Position: Q2 2015 in Review

Prelude Capital Management sold out of Filana Therapeutics (FLNA) in Q2 2015, closing a stake of 1,329 shares — an estimated $18K sold.

Prelude Capital Management first reported a position in FLNA in Q3 2014 and held it in 3 quarters. The position peaked at $79K in Q3 2014. 66 funds tracked by Wall St. Rank hold FLNA as of Q2 2015.

  • Prelude Capital Management reported no remaining Filana Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Prelude Capital Management sold 1,329 Filana Therapeutics shares in Q2 2015, an estimated $18K.
  • Prelude Capital Management first reported a position in Filana Therapeutics in Q3 2014 and held it in 3 quarters.
  • Prelude Capital Management's Filana Therapeutics position peaked at $79K in Q3 2014.
  • 66 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2015.

Based on Prelude Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.